HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature.

Abstract
Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the platelet membrane. Managing bleeding episodes is often difficult, and a variety of modalities have been used, including platelet transfusions, recombinant factor VIIa (rFVIIa), and other supportive care. The aim of this review was to present the clinical experience with rFVIIa bolus infusion (rFVIIa BI) for treatment of bleeding episodes and prevention of bleeding during surgical procedures in patients with GT. A literature search was performed to identify rFVIIa-treated patients with GT. Overall, one international survey, one open-label study, and 40 case reports identified 172 bleeding episodes treated with rFVIIa and 62 procedures covered with rFVIIa. In the international survey, rFVIIa BI was used for 96 bleeding episodes in 59 patients. Recombinant FVIIa was effective in 76 bleeding episodes (79%). Of 34 surgical procedures, 25 procedures received rFVIIa BI with 92% bleeding-prevention efficacy. The open-label study reported 28 patients with 28 rFVIIa BI-treated bleeds, and 26 (93%) bleeding episodes responded to rFVIIa. Published case reports revealed that 25 (69%) of 36 bleeds and 27 (96%) of 28 surgeries responded to rFVIIa BI treatment. Overall, 26 adverse events were reported in 19 patients, including five thromboembolic events in two patients where a possible relationship with rFVIIa could not be excluded. Two large studies and 40 case reports provide a literature base to support the efficacy and safety of rFVIIa BI in patients with GT.
AuthorsM Rajpurkar, M Chitlur, M Recht, D L Cooper
JournalHaemophilia : the official journal of the World Federation of Hemophilia (Haemophilia) Vol. 20 Issue 4 Pg. 464-71 (Jul 2014) ISSN: 1365-2516 [Electronic] England
PMID24948404 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2014 John Wiley & Sons Ltd.
Chemical References
  • Antibodies
  • Recombinant Proteins
  • recombinant FVIIa
  • Factor VIIa
Topics
  • Antibodies (immunology)
  • Factor VIIa (adverse effects, immunology, therapeutic use)
  • Humans
  • Recombinant Proteins (adverse effects, immunology, therapeutic use)
  • Safety
  • Thrombasthenia (drug therapy, immunology)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: